The Best Laboratory Execution System Is the One That Fixes Your Lab's Fragmentation Problem

If you're evaluating a laboratory execution system, you already know what the checklist looks like: 21 CFR Part 11, EU Annex 11, GxP, audit trails, electronic signatures, a workflow that enforces the SOP at the bench. Every vendor comparison runs through some version of it.

What the checklist doesn't always test for is whether the specific system you're comparing will connect to the LIMS, ELN, and instruments your lab already runs, or add one more system that doesn't talk to them.

Most labs are already living with exactly that problem. Interoperability between laboratory systems and the instruments on the bench is one of the most common obstacles reported in QC labs today.

An LES that checks every box on the standard feature checklist exacerbates that problem if it becomes yet another system to reconcile instead of the layer that connects the other three.

That's the question pharma and biotech manufacturers should be asking: does the LES you're evaluating connect to the systems your lab is already using? Or does it ask you to replace something you've already validated?

This post walks through the five criteria you should consider as you're evaluating a lab execution system, with that test applied to each. We'd argue the vendor whose LES connects to your LIMS and ELN starts from a different position than the one that asks you to replace them, and that the difference outweighs a longer features list.

A laboratory execution system (LES) is software that runs an analytical test method at the bench. It takes a written SOP and turns it into a guided, digital workflow.

Each step appears in order, tolerance and condition checks are built into the sequence, and instrument readings get captured directly rather than transcribed by hand. What comes out the other end is a defensible, audit-ready record showing exactly how the test was performed, which is what separates an LES from software that just stores or schedules results.

QC and analytical labs adopt one because the same methods run over and over, and every result has to survive an inspection.

Most regulated labs already run more than one of these systems, which is exactly why the boundaries between them tend to get blurry.

A LIMS, an LES, and an ELN all touch the same underlying things, samples, methods, results, and confusing what each one is for is a common reason labs end up buying software that duplicates a capability instead of closing a gap.

LIMS (Laboratory Information Management System) is the system of record. It tracks samples, schedules tests, stores results, and manages chain of custody. It answers what was tested and why. (We've written separately about where traditional LIMS platforms fall short and what a composable approach changes; this piece stays focused on the execution layer specifically.)

LES (Laboratory Execution System) runs the procedure itself. It guides an analyst through a test method step by step, enforces the right sequence, captures instrument readings directly, and produces a record of exactly how the test was performed. It answers how the work got done.

ELN (Electronic Lab Notebook) documents flexible, unstructured work, better suited to R&D experimentation than the repeatable, regulated procedures a QC lab runs day after day.

Many regulated labs run all three at once. The LIMS tracks the sample, the LES executes the test, and the ELN documents the research behind it.

That overlap is common, but it's also where a lot of labs' actual problems live.

The implications on compliance

The compliance backdrop attached to all of this is familiar to anyone who's worked in a regulated lab.

In the US, 21 CFR Part 11 governs electronic records and signatures, requiring that a digital record be as trustworthy as the paper one it replaces. In the EU, Annex 11 sets a parallel bar for computerized systems used in GMP-regulated work. It calls for risk-based validation, audit trails, and either a second reviewer or a validated automated check on critical steps.

GxP is the umbrella term covering all of this (GMP, GLP, GDP), and GAMP 5 is the risk-based framework underneath both the traditional Computer System Validation (CSV) approach and the FDA's newer Computer Software Assurance (CSA) guidance, finalized in September 2025, which lets labs scale validation effort to actual risk instead of documenting every change with the same exhaustive rigor.

No regulation names a laboratory execution system as a requirement, despite what a vendor may imply. A lab running paper-based methods can be GMP-compliant if the controls are followed.

In our opinion, the case for an LES rests on data integrity and review speed. It gives you a faster, more defensible way to demonstrate compliance you already have to maintain, regardless of which system does the work.

A lab that buys an LES to satisfy the compliance checklist without asking whether it connects to the systems already in place risks adding a new system to have to keep track of as opposed to fixing the problem the checklist was meant to catch.

The scale of the fragmentation problem is easy to underestimate.

Deloitte's 2025 survey of 103 biopharma executives found that 40% of QC labs are still digitally siloed, meaning data is scattered across a LIMS, an ELN, and individual instruments with limited automation between them, and that 45% name poor interoperability between lab systems and instruments as their single biggest modernization obstacle, ahead of budget, staffing, or anything else surveyed.

Only 6% of labs have reached a fully integrated, "predictive" level of maturity today, though a quarter believe they can get there within two to three years. Where labs did modernize, the results were substantial. Half reported fewer errors and deviations, 45% reported improved compliance, and 43% reported shorter testing timelines.

McKinsey's research on smart quality control points to where that gain comes from, and it isn't primarily the addition of a dedicated execution layer.

The firm attributes most of the measurable productivity improvement in QC labs to reaching what it calls "digitally enabled" status, meaning automatic data transcription between instruments and the LIMS, with no manual re-keying in between. That alone is worth a 25-45% cost reduction in a chemical QC lab, and up to 80% of manual documentation work eliminated, before a lab adds any automation or a separate execution module on top. One plant McKinsey studied saw productivity rise 30% and deviations fall 80% from digital enablement alone.

Regulators, meanwhile, aren't citing labs for lacking a dedicated execution layer. A peer-reviewed analysis of a decade of FDA CGMP warning letters (2010 to 2020) found validation deficiencies were the single largest violation category, at 26%, followed by documentation and data-integrity failures at 21%.

Each additional system boundary a batch record crosses is another potential point where those specific gaps open up. Closing them is largely a matter of tightening the seams between the systems a lab already has, not adding a new one.

Faced with this, we see labs respond in one of three ways. Some bolt a rigid LES module onto their existing LIMS, where any method change requires a vendor ticket, custom development, and a re-validation cycle.

Others reach for ungoverned point solutions, that solve one task quickly while adding another silo with no audit trail behind it.

Plenty of labs still paper over the gap with binders and spreadsheets, because that's what's familiar and already validated. Each path keeps the lab fragmented; they're just fragmented in different ways.

Most comparisons of laboratory execution systems run through the same five categories:

1. Regulatory compliance
2. Guided workflow execution
3. Instrument integration
4. Configurability
5. Deployment cost

Once you've seen the fragmentation data above, we think the question underneath each one changes. Does this capability connect to what your lab already has running, or does it ask you to replace something you've already validated? Let's explore what this looks like in practice.

Regulatory compliance and validation posture

This criterion goes beyond whether a platform simply offers audit trails and electronic signatures. It's whether the validation approach aligns to GxP and GAMP 5, or the newer CSA framework, without forcing a full CSV-style re-validation project every time something changes.

Tulip's laboratory execution system, to use one example of a connected approach, is built around 21 CFR Part 11 and ISO 17025-aligned validation, with a CSA-aligned validation model in place of a fully document-heavy CSV process.

Analysts sign off electronically within the app itself, and every record carries an automatic audit log visible in your digital history record.

Built-in governance controls enable GxP manufacturers to tighten who can assign, execute, or edit an app and adds more explicit dates and IDs to the audit record.

Whatever platform you're evaluating, confirm its specific compliance documentation directly with the vendor before you rely on it for your own regulatory filing. A features page is a starting point, but it isn't validation evidence.

Guided workflow execution and SOP enforcement

This is a different question from validation posture, which is about the paperwork behind a test.

Here, the question is what happens during the test itself. Does the system turn a written SOP into an enforced, step-by-step workflow, with tolerance checks built-in, so a reviewer can practice review by exception instead of re-checking every step by hand?

Tulip turns an SOP into an interactive app the analyst follows in the same order every time. Out-of-spec results and deviations get flagged automatically as they happen, not caught later at final review. The audit trail and e-signatures build up as part of the same flow, not as a separate task at the end.

Instrument and data integration

This is where the connect-or-replace question is most important. Does the system pull data directly from your lab instruments without anyone hand-keying a reading, and does it do that by talking to the LIMS, ELN, and ERP you already run, or by asking you to adopt a new system of record alongside them?

Tulip pulls readings straight from instruments, HPLCs and balances among them, with nothing typed in by hand, and syncs that data, along with samples and method information, with the LIMS, ELN, and ERP already in place. The traditional pattern looks different.

An LES module tied to one vendor's own LIMS suite may be useful if that's the LIMS you run, but can become a huge bottleneck if it isn't.

No-code and low-code configurability

Methods change. Reagents get swapped, new tests get added, a step gets revised after a deviation investigation.

When that happens, can your own team make the change under governance? Or does it require a vendor change request and a fresh validation cycle?

In Tulip, adapting the app to reflect a method change is something the lab does itself, without filing a vendor ticket or enlisting third-party support. That's a different question from the integration criteria above, which is about which systems the data flows through. This one is about who can make adjustments to your workflows when things inevitably change, and how fast.

Deployment model and total cost of ownership

Anyone who's implemented enterprise software before knows the price for software licenses is only part of the total cost. How long implementation takes, how much IT lift it demands, and what validation and integration add to the total all belong in the comparison too.

Traditional LES modules bundled inside a full LIMS suite often mean a multi-year, IT-heavy rollout. A composable, iterative approach can go live with a single workflow in a matter of weeks and expand from there.

Here's what these five criteria look like in practice, at the bench.

An analyst logs in and opens the assigned test method as a step-by-step app. Before the app lets her move to the next step, it checks that a tolerance or condition has been met.

When it's time to record a reading, the app pulls it directly from the instrument rather than waiting for her to type it in. If a result comes back out of spec, the app flags it immediately for review instead of letting it surface later during batch release.

When the method is complete, she signs electronically to certify it, and the app generates the record automatically, audit trail already attached, ready for review by exception rather than manual reconstruction after the fact.

We've worked through this exact process with companies like Organon, who digitized lab execution and had a live, connected GMP method running within six months.

After implementing Tulip, hands-on lab time dropped 20%, manual transcription between instruments and their systems disappeared, and review by exception became standard practice across their operations.

Importantly, this deployment didn't require replacing Organon's system of record. The value came from connecting instrument data and workflow execution to what was already validated and running, the same distinction running through all five criteria above.

Whether the five criteria above help you comes down to one thing. Does the platform you're evaluating treat your existing LIMS and ELN as something to build on, or something to work around?

Three questions turn that distinction into a real vendor conversation.

1. Does this connect to your current LIMS and ELN, or does it require migrating off them?
2. When you change a method, who owns the re-validation, the vendor or your own team?
3. And what does day-one deployment look like in practice, a single workflow running in a matter of weeks, or a multi-year implementation program?

If your lab is one of the many still working across a LIMS, an ELN, and a shelf of instruments that don't share data, we'd rather show you how Tulip's laboratory execution system connects to what you already run than ask you to start over. Schedule a demo to see what that looks like for your lab.